There are parallels with Solagran and BioProspect projects as well as executive teams. However there are critical differences too. There are many good reasons to keep an arms length arrangement. As for BioProspect it has a biota library which currently includes 20 pure novel compounds to date -this is a resource that can not be undervalued. The scope of these compounds is potentially vast.
